John Todd Koning Sells 37,500 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) CFO John Todd Koning sold 37,500 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $12.82, for a total value of $480,750.00. Following the completion of the sale, the chief financial officer now owns 393,356 shares of the company’s stock, valued at $5,042,823.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

John Todd Koning also recently made the following trade(s):

• On Friday, March 1st, John Todd Koning sold 121,601 shares of Alphatec stock. The stock was sold at an average price of $13.30, for a total value of $1,617,293.30.

Alphatec Trading Up 1.6 %

NASDAQ:ATEC opened at $12.44 on Friday. The firm has a market cap of $1.72 billion, a PE ratio of -8.03 and a beta of 1.55. The stock has a fifty day moving average price of $13.63 and a 200 day moving average price of $13.46. Alphatec Holdings, Inc. has a 12-month low of $8.66 and a 12-month high of $19.14. The company has a current ratio of 2.86, a quick ratio of 1.99 and a debt-to-equity ratio of 6.54.

Alphatec (NASDAQ:ATEC) last released its earnings results on Tuesday, February 27th. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.09). The company had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $131.90 million. The company’s revenue for the quarter was up 30.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.33) EPS. Sell-side analysts anticipate that Alphatec Holdings, Inc. will post -1.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ATEC has been the subject of several recent analyst reports. Needham & Company LLC raised their target price on Alphatec from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, March 28th. Wells Fargo & Company initiated coverage on Alphatec in a research note on Friday, February 9th. They set an “overweight” rating and a $26.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Alphatec in a research note on Monday, March 4th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $25.00 price target on shares of Alphatec in a research report on Wednesday, March 20th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.63.

Institutional Trading of Alphatec

A number of institutional investors have recently bought and sold shares of ATEC. AE Wealth Management LLC purchased a new stake in Alphatec during the 3rd quarter worth about $423,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Alphatec by 23.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,120 shares of the medical technology company’s stock worth $157,000 after buying an additional 2,331 shares during the last quarter. BluePath Capital Management LLC purchased a new stake in Alphatec during the 3rd quarter worth about $29,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Alphatec by 10.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 44,509 shares of the medical technology company’s stock worth $577,000 after buying an additional 4,210 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Alphatec by 140.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 13,797 shares of the medical technology company’s stock worth $179,000 after buying an additional 8,065 shares during the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.